jzs-10803

The Estimate of Cytokines and Fibroblast Growth Factors in Patients with Breast Cancer

Shvan Burhan Rafiq1, Heshu Sulaiman Rahman2, Kawa Amin3,4,*

1Department of Clinical Biochemistry, College of Pharmacy, University of Sulaimani, Sulaimani, Kurdistan Region- Iraq 

2Department of Physiology, College of Medicine, University of Sulaimani, Sulaimani, Kurdistan Region- Iraq

3Department of Microbiology/Immunology, College of Medicine, University of Sulaimani, Sulaimani, Kurdistan Region- Iraq 

4Department of Medical Science, Respiratory Medicine and Allergology. Uppsala University and University Hospital, Uppsala, Sweden

Corresponding author’s e-mail: kawa.amin@univsul.edu.iq*

Original: 2 September 2020        Revised: 9 October 2020        Accepted: 9 November 2020        Published online: 20 December 2020  

Doi Link:

Abstract

Breast cancer is the most common cancer in women worldwide; it is a disease characterized by the growth of malignant cells within the mammary glands. It strikes males and females; there are diverse sorts of breast cancer. Cytokines and fibroblast growth factors that play a critical role in the development and progression of breast cancer. The aim of the present study is to assess the role and the level of certain cytokines, and fibroblast growth factors in the serum of patients with breast cancer. This is case-control study, blood samples were collected randomly from 60 newly diagnosed female patients, and 60 healthy female subject controls of all age groups. Venous blood samples were collected and analyzed for cytokines (Interleukin-19 and Interleukin-23) and fibroblast growth factors (FGF-18 and FGF-23) by using ELISA. There was a highly significant difference (p <0.001) detected in serum IL-19, IL-23, and FGF-18 levels of patients compared to healthy controls except for FGF-23, which was also recorded higher value in patients but not significantly compared to controls. There was a significant positive correlation (p <0.001) between all these markers. The present study reveals significantly higher concentrations of the markers detected in patients’ blood serum compared to healthy individuals. The detection of the cytokines’ levels and their relations with breast cancer will affect the diagnosis, knowledge about the disease immunology and thereafter effects on the treatments of patients with breast cancer depending on our findings.

Key Words: Breast cancer, Cytokines, Fibroblast, Immune system, Inflammation, ELISA

References

[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. "Global cancer statistics 2012". CA Cancer J Clin. Vol. 65, No. 2, pp. 87-108. 2015).

[2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". CA Cancer J. Clin. Vol. 68, No. 6, pp. 394-424. (2018).

[3] Moodley J, Cairncross L, Naiker T, Constant D. "From symptom discovery to treatment - women's pathways to breast cancer care: a cross-sectional study". BMC Cancer. Vol. 18, No. 1, pp. 312. (2018).

[4] Yager JD, Davidson NE. "Estrogen carcinogenesis in breast cancer". N. Engl J. Med. Vol. 354, No. 3, pp. 270-82. (2006).

[5] Dmitrieva OS, Shilovskiy IP, Khaitov MR, Grivennikov SI. "Interleukins 1 and 6 as Main Mediators of Inflammation and Cancer". Biochemistry (Mosc). Vol. 81, No. 2, pp. 80-90. (2016).

[6] Paduch R, Walter-Croneck A, Zdzisińska B, Szuster-Ciesielska A, "Kandefer-Szerszeń M. Role of reactive oxygen species (ROS), metalloproteinase-2 (MMP-2) and interleukin-6 (IL-6) in direct interactions between tumour cell spheroids and endothelial cell monolayer". Cell Biol Int. Vol. 29, No. 7, pp. 497-505. (2005).

[7] Menon R, Ismail L, Ismail D, Merialdi M, Lombardi SJ, Fortunato SJ. "Human fetal membrane expression of IL-19 and IL-20 and its differential effect on inflammatory cytokine production". J. Matern. Fetal. Neona. Vol. 19, No. 4, pp. 209-214. (2006).

[8] Tang C, Chen S, Qian H, Huang W. "Interleukin-23: as a drug target for autoimmune inflammatory diseases". Immunology. Vol. 135, No. 2, pp. 112-124. (2012).

[9] Sheng S, Zhang J, Ai J, Hao X, Luan R. "Aberrant expression of IL-23/IL-23R in patients with breast cancer and its clinical significance". Molecular medicine reports. Vol. 17, No. 3, pp. 4639-44. (2018).

[10] Diez del Corral R, Breitkreuz DN, Storey KG. "Onset of neuronal differentiation is regulated by paraxial mesoderm and requires attenuation of FGF signalling". Development. Vol. 129, No. 7, pp. 1681-1691. (2002).

[11] Majidinia M, Sadeghpour A, Yousefi B. "The roles of signaling pathways in bone repair and regeneration". J. Cell Physiol. Vol. 233, No. 4, pp. 2937-2948. (2018).

[12] Yu Z, Lou L, Zhao Y. "Fibroblast growth factor 18 promotes the growth, migration and invasion of MDA‑MB‑231 cells". Oncology reports. Vol. 40, No. 2, pp. 704-714. (2018).

[13] Ohbayashi N, Shibayama M, Kurotaki Y, Imanishi M, Fujimori T, Itoh N, et al. "FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis". Genes Dev.  Vol. 16, No. 7, pp. 870-879. (2002).

[14] Sonvilla G, Allerstorfer S, Stättner S, Karner J, Klimpfinger M, Fischer H, et al. "FGF18 in colorectal tumour cells: autocrine and paracrine effects". Carcinogenesis. Vol. 29, No. 1, pp. 15-24. (2008).

[15] Wei W, Mok SC, Oliva E, Kim S-h, Mohapatra G, Birrer MJ. "FGF18 as a prognostic and therapeutic biomarker in ovarian cancer". J. Clin. Invest. Vol. 123, No. 10, pp. 4435-4448. (2013).

[16] Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. "Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia". Proc. Natl. Acad. Sci. USA. Vol. 98, No. 11, pp. 6500-6505. (2001).

[17]Liu S, Guo R, Simpson LG, Xiao Z-S, Burnham CE, Quarles LD. "Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX". J Biol Chem. Vol. 278, No. 39, pp. 37419-26. (2003).

[18] de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al."Abiraterone and increased survival in metastatic prostate cancer". The New England journal of medicine. Vol. 364, No. 21, pp. 1995-2005. (2011).

[19] Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, et al. "Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER(+) Breast Cancer". Clinical cancer research : an official journal of the American Association for Cancer Research. Vol. 23, No. 20, pp. 6138-6150. (2017).

[20] Chen YY, Li CF, Yeh CH, Chang MS, Hsing CH. "Interleukin-19 in breast cancer". Clinical & developmental immunology. Vol. 2013, pp. 294-320. (2013).

[21] Hsing CH, Cheng HC, Hsu YH, Chan CH, Yeh CH, Li CF, et al. "Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome". Clinical cancer research : an official journal of the American Association for Cancer Research. Vol: 18, No. 3, pp. 713-725. (2012).

[22] Gangemi S, Minciullo P, Adamo B, Franchina T, Ricciardi GR, Ferraro M, et al. "Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients". Journal of cellular biochemistry. Vol. 113, No. 6, pp. 2122-2125. (2012).

[23] Ishihara-Yusa S, Fujimura T, Lyu C, Sugawara M, Sakamoto K, Aiba S. "Breast Cancer Metastasis in the Skin with Hyperkeratotic Pigmentation Caused by Melanocyte Colonization". Case reports in oncology. Vol. 11, No. 3, pp. 660-664. (2018).

[24] Song N, Zhong J, Hu Q, Gu T, Yang B, Zhang J, et al. "FGF18 Enhances Migration and the Epithelial-Mesenchymal Transition in Breast Cancer by Regulating Akt/GSK3beta/Beta-Catenin Signaling". Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. Vol. 49, No. 3, pp. 1019-1032. (2018).

[25] Yu Z, Lou L, Zhao Y. "Fibroblast growth factor 18 promotes the growth, migration and invasion of MDAMB231 cells". Oncology reports. Vol. 40, No. 2, pp. 704-714. (2018).

[26] Ben-Aharon I, Levi M, Margel D, Yerushalmi R, Rizel S, Perry S, et al. "Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?" Oncotarget. Vol. 9, No. 22, pp. 15931-15941. (2018).

[27] Brooks AN, Kilgour E, Smith PD. "Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer". Clinical Cancer Research. Vol. 18, No. 7, pp. 1855-1862. (2012).

View Full Article